Cryo-Cell International Inc. (NYSE American LLC: CCEL), the pioneering private cord blood bank, has released its financial results for the fiscal second quarter ending May 31, 2025. The company reported revenues of $7.9 million, marking a slight decrease from $8.0 million in the same period of fiscal 2024. The revenue breakdown for the second quarter of 2025 included $7.87 million from processing and storage fees, $43,000 from public banking, and $14,000 from product sales, compared to $7.97 million, $41,000, and $36,000, respectively, in the previous year. Net income for the quarter stood at $356,000, or $0.04 per basic and diluted share, a decline from $656,000, or $0.08 per share, in the equivalent quarter of the prior year. The company did not provide any outlook or guidance in the current release.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。